Melatonin Antagonizes Nickel-Induced Aerobic Glycolysis by Blocking ROS-Mediated HIF-1α/miR210/ISCU Axis Activation

Mindi He, Chao Zhou, Yonghui Lu, Ling Mao, Yu Xi, Xiang Mei, Xue Wang, Lei Zhang, Zhengping Yu, and Zhou Zhou

1Department of Occupational Health, Army Medical University, 400038 Chongqing, China
2Department of Environmental Medicine, School of Public Health, and Department of Emergency Medicine, First Affiliated Hospital, School of Medicine, Zhejiang University, 310058 Hangzhou, China

Correspondence should be addressed to Zhou Zhou; lunazhou@zju.edu.cn

Received 18 February 2020; Revised 10 April 2020; Accepted 29 April 2020; Published 29 May 2020

1. Introduction

Nickel and its compounds, which are well-documented carcinogens, induce the Warburg effect in normal cells by stabilizing hypoxia-inducible factor 1α (HIF-1α). Melatonin has shown diverse anticancer properties for its reactive oxygen species- (ROS-) scavenging ability. Our aim was to explore how melatonin antagonized a nickel-induced increment in aerobic glycolysis. In the current work, a normal human bronchial epithelium cell line (BEAS-2B) was exposed to a series of nonlethal doses of NiCl₂, with or without 1 mM melatonin. Melatonin attenuated nickel-enhanced aerobic glycolysis. The inhibition effects on aerobic glycolysis were attributed to the capability of melatonin to suppress the regulatory axis comprising HIF-1α, microRNA210 (miR210), and iron-sulfur cluster assembly scaffold protein (ISCU1/2). N-Acetylcysteine (NAC) manifested similar effects as melatonin in scavenging ROS, maintaining prolyl-hydroxylase activity, and mitigating HIF-1α transcriptional activity in nickel-exposed cells. Our results indicated that ROS generation contributed to nickel-caused HIF-1α stabilization and downstream signal activation. Melatonin could antagonize HIF-1α-controlled aerobic glycolysis through ROS scavenging.
(OXPHOS) such as aconitase and NADH-coenzyme Q reductase (complex I) are inactivated, leading to OXPHOS suppression [8]. This axis has been proven to mediate several physiologic and pathologic processes associated with hypoxia [10–13]. Notably, hypoxia is not the only factor that stabilizes HIF-1α through prolyl-hydroxylase enzyme (PHD) inhibition. Other factors, such as ROS, succinate, deferoxamine, and CoCl2, have been found to cause HIF-1α accumulation through different mechanisms [9, 14]. Interestingly, the stabilization of HIF-1α by nickel under normoxia is a well-known effect that is believed to play a key role in nickel-associated carcinogenesis [15]. It is quite natural to investigate whether this regulatory axis underlies aerobic glycolysis under nickel exposure conditions.

In recent years, the ability of melatonin to destabilize HIF-1α has been repeatedly investigated regarding the anti-cancer effects of melatonin [16–19]. The vascular endothelial growth factor- (VEGF-) mediated angiogenesis is attenuated by melatonin through destabilizing HIF-1α in different tumor cells [20–22]. Melatonin was also reported to inhibit tumor cells through reversing aerobic glycolysis [6, 23]. According to the published literature, melatonin destabilizes HIF-1α via diverse routes depending on the cell type or treatment procedure [9]. Sohn et al. reported that miR3195 and miRNA374b account for the melatonin-induced HIF-1α mRNA decrease in PC-3 prostate cancer cells [24]. Park et al. reported that melatonin downregulates HIF-1α expression through the inhibition of protein translation in prostate cancer cells [25]. Nevertheless, many studies have focused on the protective effect of melatonin on PHD, whose inactivation dramatically causes HIF-1α accumulation. In addition to oxygen, ascorbic acid is also necessary for PHD catalytic activity [9]. Melatonin may maintain PHD activity through its antioxidant capability. Considering that multiple metals can stabilize HIF-1α [4], investigating whether and how melatonin ameliorates HIF-1α accumulation may increase the knowledge of the melatonin protective effect against heavy metal-associated toxicity [26, 27].

In the present study, we investigated the suppressive effect of melatonin on aerobic glycolysis induced by nickel. The mediating roles of the HIF-1α/miR210/ISCU1/2 axis were elucidated in a cell model that exposed human bronchial epithelial cells to nonlethal doses of nickel. A pharmacological dose of melatonin (1 mM) in cell culture studies [9] was applied to investigate potential mechanism of melatonin destabilizing HIF-1α.

2. Materials and Methods

2.1. Cell Culture and Treatments. Human bronchial epithelial cells (BEAS-2B) were purchased from the Institute of Biochemistry and Cell Biology (Chinese Academy of Science, Shanghai, China). Cells were cultured in RPMI 1640 medium (HyClone, Logan, UT, USA) supplemented with 10% fetal bovine serum (FBS; HyClone) and 1% v/v penicillin/streptomycin (Beyotime, Shanghai, China) and were grown at 37°C in a 5% CO2 humidified incubator. At the confluence of 75-85%, the cells were subcultured into plates or dishes for treatments. Nickel chloride (NiCl2·6H2O) and melatonin (Sigma-Aldrich, St. Louis, MO, USA) were dissolved with sterile H2O and absolute ethyl alcohol, respectively, and then were diluted to the appropriate concentrations with cells in medium. The doses of NiCl2 and melatonin were chosen based on reported studies and our preliminary experiments. At the 18 h post-NiCl2 administration, melatonin was added into the wells and incubated with cells for an additional 6 h. Potential HIF-1α inhibitors, namely, 2-deoxyglucose (2-DG), α-ketoglutarate (α-KG), NAC, and rapamycin, were used to treat cells with the same procedure as melatonin. MG132, a proteasomal inhibitor, was applied to treat cells at 10 μM for 1 h.

2.2. Cell Viability. The viability of cells is evaluated with a Cell Counting Kit-8 (CCK8, Dojindo, Kumamoto, Japan), which performs colorimetric assays for the determination of the metabolic activity of living cells. Cells were seeded into a 96-well plate (1 × 104 per well) and were exposed to NiCl2 for 18 h. Melatonin and bromopyruvic acid (BrPA; 25 μM) were added into the nickel-containing medium which was incubated for an additional 6 h. Next, the medium was replaced with fresh medium containing 10% v/v CCK8 solution and incubated for 1 h at 37°C, according to the manual of the kit. The optical density (OD) value of each well was determined at a wavelength of 450 nm using a microplate reader (Infinite™ M200, Tecan, Männedorf, Switzerland). Cell viability was expressed as a percent of the control value.

2.3. Lactate Dehydrogenase (LDH) Release. LDH release was detected using a Cytotoxicity Detection Kit (Roche, Mannheim, Germany), which measured colorimetric assays for the determination of the metabolic activity of living cells. Cells were seeded into a 96-well plate (1 × 104 per well) and were maintained in low-serum (1% FBS) medium, replaced with fresh medium containing 10% v/v v/v LFRL (2-DG), α-ketoglutarate (α-KG), NAC, and rapamycin, were used to treat cells with the same procedure as melatonin. MG132, a proteasomal inhibitor, was applied to treat cells at 10 μM for 1 h.

2.4. Glycolysis Assay. Glycolysis level was indicated by the extracellular acidification rate (ECAR) in media surrounding intact cells, which was carried on an extracellular flux analyzer (Seahorse® Bioscience, MA) as described [28]. Cells (1 × 104 per well) were plated into a dedicated microplate (XP96V3 PS; Seahorse Bioscience, MA) and were treated with NiCl2 and melatonin. After 10 mM glucose was injected into a well, ECAR was determined by quantifying H+ -dependent changes in the fluorescence of a proprietary fluorescein complex. The glycolysis level of each group was expressed as a percent of the control value.

2.5. PFK Activity Assay. The activity of phosphofructokinase (PFK) was measured using the PFK Activity Colorimetric Assay Kit (Sigma-Aldrich, St. Louis, MO, USA), by which PFK-mediated NADH generation in the reaction mix is reflected by the OD change at 450 nm. Treated cells were
homogenized with PFK Assay Buffer. Cell lysis was performed using the Reaction Mix prepared according to the manufacturer’s instructions. The OD of the mixtures was measured per 30 s with the microplate reader. A NADH standard was also established for PFK activity calculation. One unit of PFK is the amount of enzyme that generates 1.0 μM of NADH per minute. After normalization of the protein concentration, the PFK activity was expressed as milliunits/mg of protein.

2.6. ATP Assay. The adenosine-5′-triphosphate (ATP) content was determined using the ATP Determination Kit (Life Technologies, Carlsbad, CA). The assay is based on luciferase’s absolute requirement for ATP in producing light. Cells were seeded into 12-well plates (1 × 10^5 per well) and were treated with NiCl2 and melatonin. After treatment, the cells were lysed with 100 μl of RIPA buffer (Beyotime) and were centrifuged at 10000 × g for 15 min. Next, 20 μl of supernatant was mixed with 100 μl of determination buffer in a white 96-well plate. The luminescence of each well was measured using the microplate reader. ATP standard curves were established, and the ATP content was expressed as nmol/mg of protein.

2.7. Lactate Assay. The intracellular lactate content was measured using the Lactate Determination Kit (Jiancheng, Nanjing, China). In this kit, lactate concentration is determined by an enzymatic assay, which results in a colorimetric product. Briefly, 20 μl of cell lysate was reacted with 1 ml of the determination buffer for 10 min at 37°C. The OD of the final mixtures was measured at a wavelength of 570 nm. Standard curves were established, and the lactate concentration was expressed as μM/mg of protein.

2.8. Aconitase and Complex I Activity Assays. Colorimetric assay-based typical FeS metabolic enzyme measurements were performed as in a previous study [8]. The activity of aconitase was reflected by the conversion of cis-aconitate to isocitrate. In this assay, isocitrate dehydrogenase excess is used, which catalyzes the oxidation of isocitrate into α-ketoglutarate. This reaction couples to the reduction of NADP+, which is monitored at 340 nm. The activity of complex I, which is proportional to the rate of NADH oxidation, is measured by a decrease in absorbance at 340 nm. The cells were plated into a 60 mm dish for these two enzyme activity measurements. After appropriate treatment, the cells were collected in Eppendorf tubes, resuspended in hypotonic buffer (120 mM KCl, 20 mM HEPES, 2 mM MgCl2, and 1 mM EGTA, pH 7.4), and disrupted by performing ten 1 s pulses using a Vibra-Cell ultrasonic processor (Sonics & Materials Inc., Danbury, CT). The reaction media for aconitase (5 mM sodium citrate, 0.6 mM MnCl2, 0.2 mM NADP+, 1.5 mM isocitrate dehydrogenase, and 50 mM Tris-Cl, pH 7.4) or complex I activity assays (25 mM potassium phosphate, 5 mM MgCl2, 0.13 mM NADH, 65 μM ubiquinone 1, 2 mM NaCN, 2 μg/ml antimycin A, and 2.5 mg/ml BSA, pH 7.4) were prepared and prewarmed at 37°C. Next, 20 μl of lysate was mixed with 180 μl of reaction medium in a 96-well plate (μClear®; Greiner Bio-One, Germany). The activity of aconitase or complex I was indicated by the optical density change of each well at 340 nm and was expressed as a percent of the control value.

2.9. Immunofluorescence Staining. For the immunofluorescence assay, cells were grown on gelatin-coated glass coverslips. After appropriate treatments, the cells were fixed with 4% (w/v) paraformaldehyde in PBS for 30 min, followed by permeabilization with 0.25% Triton X-100 in PBS for 10 min. Next, the cells were blocked with 10% BSA in PBS. The fixed cells were incubated with rabbit anti-ISCU1/2 (1 : 20; Santa Cruz Biotechnology Inc., Santa Cruz, CA) antibody in blocking buffer at 4°C overnight. The slides were then washed five times with PBS and were incubated with an Alexa Fluor® 488 donkey anti-rabbit IgG (H+L) antibody (1 : 500; Invitrogen, Carlsbad, CA) for 1 h at 37°C. DAPI Staining Solution (Beyotime) was used for nuclear counterstaining. The coverslips were mounted on glass slides using Antifade Mounting Medium (Beyotime). The stained samples were examined using a Zeiss confocal laser scanning microscope (Zeiss, LSM 780). The images were captured and processed using Zeiss LSM 780 software.

2.10. Western Blotting. Protein samples (20-40 μg) from treated cell extracts were resolved by 10% or 12% SDS-PAGE gel and were transferred to a polyvinylidene fluoride membrane (Bio-Rad, Hercules, CA). The membranes were probed for various proteins using the appropriate antibodies (primary antibody incubated overnight at 4°C, secondary antibody incubated for 1 h at room temperature) and were visualized using an electrochemiluminescence (ECL) system (Thermo Fisher Scientific, Waltham, MA). The bands were imaged and analyzed using the ChemiDoc™ XRS+ System with Image Lab™ Software (Bio-Rad, Hercules, CA). The applied primary antibodies included HIF-1α (1 : 1000 Novus Biologicals, Littleton, CO), hydroxy-HIF-1α (1 : 1000 Cell Signaling Technology, Danvers, MA), ISCU1/2 (1 : 200 Santa Cruz Biotechnology, Santa Cruz, CA), aconitase 2 (1 : 1000), and NDUF9 (1 : 2000, Abcam, Cambridge, UK).

2.11. Cell Transfection. ISCU1/2 siRNA (h) (sc-270108) and control siRNA (sc-37007) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). miR210 mimic (miR1000267), mimic control (miR01201), miR210 inhibitor (miR20000267), and inhibitor control (miR22021) were purchased from RiboBio Co. Ltd. (Guangzhou, China). The oligonucleotides were transfected into cells according to the manufacturer’s instructions. Briefly, 24 h after cell seeding, medium without penicillin/streptomycin was replaced with the transfection medium containing the oligonucleotides (200 nM ISCU1/2 siRNA, 100 nM miR210 mimic or inhibitor) and 0.2% v/v Lipofectamine 2000 transfection reagent (Invitrogen, Carlsbad, CA). After 4 h of incubation, the transfection medium was replaced with fresh penicillin/streptomycin-free medium for 24 h before subsequent experiments. HIF-1α-specific short hairpin RNAs (shRNA) were designed and packaged into lentivirus by GeneChem Inc. (Shanghai, China). After testing, the most effective construct (target sequence: GCGAAGTAAAGAATCTGAA)
was applied in formal experiments. To knock down HIF-1α, the cells were seeded into culture plates 1 day prior to infection. The culture medium was replaced by the infection medium containing 5 μg/ml of polybrene and the packed lentivirus with a multiplicity of infection (MOI) of 20. Twelve hours later, the infection medium was replaced with fresh culture medium. Cells were cultured for an additional 48 h before nickel treatment.

2.12. qRT-PCR Analysis. The extraction of total RNA and quantification of miR210 were performed following our previously published protocol [3]. The bulge-loop miRNA qRT-PCR primer sets (one reverse transcription primer and a pair of quantitative PCR primers for each set, MQP-0102 and MQP-0201) were designed by RiboBio Co. Ltd. (Guangzhou, China). U6 was utilized as an internal control for miRNA.

2.13. Electrophoresis Mobility Shift Assay (EMSA). Electrophoresis mobility shift assay was applied to test the DNA binding activity of HIF-1α. Both biotin-labeled and non-labeled cold competitor oligonucleotide probes for HIF-1α were purchased from Beyotime. The oligonucleotide probe sequences were 5′-TCT GTA CGT GAC CAC ACT CAC CTC-3′ and 3′-AGA CAT GCA CTG GTG TGA GTG GAG-5′. After treatment, cell nuclear proteins were extracted using a nuclear protein extract kit (Beyotime). The reaction mixtures that contained 10 μg of nuclear proteins, 20 nM labeled probes, 2.5% glycerol, 5 mM MgCl₂, 50 ng/μl poly (dl-dC), 0.05% NP-40 and 1x binding buffer (LightShift™ Chemiluminescent EMSA Kit, Thermo Fisher Scientific) were incubated for 20 min at room temperature. The competition reactions were performed by adding 50-fold excess of unlabeled probe to the reaction mixture, while the negative control reactions had no protein sample. Electrophoresis was performed at 10 V/cm using 6% native polyacrylamide gels, and then the shifted samples were transferred to a positively charged nitrocellulose membrane. The membrane was then UV-cross-linked, blocked, and detected with a gel imaging system (Bio-Rad). Three independent experiments were carried out.

Figure 1: Effect of melatonin on nickel and BrPA coexposure induced cytotoxicity. Single nickel exposure induced cytotoxicity in BEAS-2B cells was measured with cell viability and LDH release experiments. Cells exposed to different concentrations of NiCl₂ (50-1600 μM) for 24 h (a and b). A glycolysis inhibitor, bromopyruvic acid (BrPA), was applied to coexpose with nickel. At the approach of 18 h post NiCl₂ administration, 1 mM melatonin was added and incubated with cells for an additional 6 h. The effect of melatonin on BrPA and NiCl₂ cotreatment induced cell death was measured with cell viability (c) and LDH release (d). The error bar reflects the S.E.M. of at least three independent experiments. *P < 0.05 compared with the nickel-free control group, and †P < 0.05 compared with the same nickel concentration but with the melatonin-free group.
2.14. Statistical Analysis. Values are expressed as means ± S.E.M. and were analyzed by SPSS (V18.0.0). Data comparisons were completed using one-way ANOVA or paired t-test to compare the means of different treatment groups. P < 0.05 was considered statistically significant.

3. Results

3.1. BrPA Exacerbates the Cytotoxicity of Nickel. Nickel-induced cytotoxicity was measured by cell viability and LDH release assays. Single exposures to NiCl₂ for 24 h did not induce significant cell death in BEAS-2B cells until the dose was over 800 μM (Figures 1(a) and 1(b)). A single administration of bromopyruvic acid (BrPA), a glycolysis inhibitor, also did not impact cell death. However, the coexposure of NiCl₂ and BrPA led to cell death, as demonstrated by the cell viability decrease and LDH release increase. These toxicities were ameliorated by melatonin administration (Figures 1(c) and 1(d)). Suppressing glycolysis exacerbates the toxicity of nickel, indicating that aerobic glycolysis may facilitate cell survival under nickel exposure conditions.

3.2. Melatonin Antagonizes Nickel-Induced Aerobic Glycolysis. Using a Seahorse® extracellular flux analyzer, the cellular glycolysis levels were manifested by the glucose-induced extracellular proton increase. Glycolysis activity was increased in cells exposed to NiCl₂ at 200 and 400 μM compared with that in control cells (Figure 2(a)). Phosphofructokinase (PFK), a key enzyme for glycolysis, were measured with a colorimetric based kit (b). Cellular energy metabolite levels, including the concentrations of ATP (c) and lactic acid (d), were measured in treated cells. The error bar reflects the S.E.M. of at least three independent experiments. *P < 0.05 compared with nickel-free control group, and #P < 0.05 compared with the same nickel concentration but with the melatonin-free group.
NiCl₂-treated cells (Figure 2(d)). Interestingly, melatonin treatment diminished glycolysis levels, PFK activities, and lactic acid increase but restored the ATP levels in nickel-exposed cells (Figures 2(a)–2(d)).

3.3. Melatonin Reverses Nickel-Induced Suppression of the Activities of FeS-Dependent Metabolic Enzymes. Cellular OXPHOS depends on a series of FeS-dependent metabolic enzymes, in which FeS acts as a catalysis center. The activities of aconitase and mitochondrial respiratory chain complex I, both of which contain the FeS cluster, were measured after nickel and melatonin treatments. As shown in Figures 3(a) and 3(b), the activities of these two enzymes were suppressed by nickel, but the repression was restored in the presence of melatonin. Notably, the protective effects of melatonin on FeS-containing enzyme activities were not accompanied with the increase of protein amounts of these enzyme components (ACO2 for aconitase, NDUFA9 for complex I), as shown in Figures 3(c) and 3(d). These results indicated the roles of melatonin on maintaining FeS clusters.

3.4. Melatonin Restores Nickel-Induced Decrease in the ISCU Protein Levels. To investigate the mechanism of melatonin antagonizing nickel-induced glycolysis, the levels of HIF-1α/miR210/ISCU1/2 were analyzed one by one. First, the protein levels of ISCU1/2, the key molecule for FeS assembly, were evaluated by both immunofluorescence staining and immunoblotting. Nickel exposure reduced the protein levels of ISCU1/2. However, these reductions were reversed by melatonin administration (Figures 4(a) and 4(b)). The effects of melatonin that maintained both the protein levels of ISCU1/2 and the activities of FeS-dependent enzymes were diminished by the knockdown of ISCU1/2 expression with ISCU1/2 siRNA (Figures 4(c)–4(e)).

3.5. Melatonin Blocks Nickel-Induced Overexpression of miR210. In the HIF-1α/miR210/ISCU1/2 regulatory axis, ISCU1/2 protein levels are reduced in case of miR210 overexpression. As expected, NiCl₂ induced a sharp increase in miR210 expression, while melatonin treatment significantly repressed miR210 overexpression (Figure 5(a)). Using chemically synthesized oligonucleotides, we artificially upregulated (miR210 mimics) or downregulated (miR210 inhibitor) the expression of miR210. The miR210 inhibitor did not have an effect on NiCl₂-induced HIF-1α accumulation (Figure 5(b)) but reversed the nickel-induced reduction of ISCU1/2 (Figure 5(c)), similar to melatonin. The miR210 mimics did not have an effect on melatonin mediating HIF-1α destabilization (Figure 5(d)) but diminished the effects of melatonin on the ISCU1/2 level (Figure 5(e)).

3.6. Melatonin Attenuates Nickel-Induced Accumulation of HIF-1α. Melatonin remarkably reduced the nickel-induced HIF-1α accumulation (Figure 6(a)). Similar to the effect of melatonin, the knockdown of HIF-1α expression with
lentivirus transfection ameliorated the nickel-induced HIF-1α accumulation (Figure 6(b)), miR210 overexpression (Figure 6(c)), and ISCU1/2 protein level reduction (Figure 6(d)). Notably, under the conditions of HIF-1α silencing, melatonin treatment did not additionally impact the levels of HIF-1α, miR210, or ISCU1/2 (Figures 6(b)–6(d)).
Figure 5: Effects of melatonin on nickel-induced alteration of miR210 expression. The levels of miR210 expression in cells exposed to nickel with or without melatonin were evaluated by qRT-PCR (a). Chemically synthesized oligonucleotides were transfected into cells to control the function of miR210. The effects of melatonin on nickel-caused alteration of HIF-1α (b and d) and ISCU1/2 (c and e) were evaluated under conditions of miR210 inhibiting or mimicking. The error bar reflects the S.E.M of at least three independent experiments. *P < 0.05 compared with the nickel-free control group, and #P < 0.05 compared with the same nickel concentration but with the melatonin-free group.
3.7. NAC Manifests a Similar Effect with Melatonin on Inactivation of the HIF-1α/miR210/ISCU1/2 Axis. To explore the mechanism by which melatonin ameliorated the nickel-induced HIF-1α activation, several compounds that reportedly inhibit HIF-1α under specific conditions were tested using the same treatment procedure as melatonin. Two doses of each compound were applied to cover their effect dose range. Among them, 2-DG and the α-KG derivative repressed nickel-induced HIF-1α accumulation but failed to suppress miR210 overexpression (Figures 7(a) and 7(c)). Rapamycin, an inhibitor of mTOR, had no effects on both HIF-1α and miR210 increase. However, N-acetylcysteine, a ROS scavenger, attenuated nickel-induced HIF-1α accumulation and miR210 overexpression, similar to melatonin (Figures 7(b) and 7(d)).

3.8. Melatonin Preserves PHD Activity through ROS Scavenging. To further confirm the role of ROS scavenging of melatonin in HIF-1α activation, melatonin and NAC were parallel administered in nickel-exposed cells. As expected, both melatonin and NAC ameliorated the nickel-caused ROS level increase (Figure 8(a)). The DNA binding activity of HIF-1α triggered by nickel was also suppressed by melatonin and NAC treatment, as shown by EMSA (Figure 8(b)).
has been well established that hypoxia or hypoxia-mimicking chemical agents caused HIF-1α accumulation which is mainly attributed to PHD inhibition and subsequent proteasomal degradation repression. Nickel disturbed the activity of PHD, manifesting by a decreased hydroxy-HIF-1α level. Both melatonin and NAC abrogated the hydroxy-HIF-1α decrease (Figure 8(c)). MG132, a proteasomal inhibitor, also led to HIF-1α accumulation for its capability to block protein degradation. Melatonin moderately attenuated MG132-caused HIF-1α accumulation, which was less efficient than how it attenuated nickel-induced HIF-1α accumulation (Figure 8(d)).

4. Discussion

Unlike those well-documented DNA mutagens, such as radiation and benzopyrene, the ability of nickel to break DNA is weak [4, 29]. Although the evidence regarding nickel’s relationship with cancer is abundant, the underlying mechanism of nickel carcinogenesis remains unclear. In the present study, we observed that a nonlethal dose of nickel increased glycolysis in BEAS-2B cells. The cell line and nickel dose are comparable to those applied in other nickel carcinogenesis researches [30, 31]. Our finding is in accord with the concept that aerobic glycolysis is a potential contributor for nickel carcinogenesis [2, 32]. Considering that glycolysis is involved in a series of chronic pathological processes, such as carcinogenesis, inflammation, and fibrosis [33–35], the effect of melatonin to block glycolysis may provide a new clue for its pharmacological application [36].

Melatonin is considered a full-service anticancer agent that inhibits cancer initiation, progression, and metastasis [37]. Specific to suppressing aerobic glycolysis, Hevi et al. reported that melatonin mediates energy metabolism through reducing glucose uptake in prostate cancer cells [38]. The administration of melatonin induces Ewing sarcoma cell death. Accompanying cell death, melatonin downregulates glucose uptake, depletes glycogen stores, and attenuates intracellular lactic acid accumulation [23]. More interestingly, physiological nocturnal blood levels of melatonin inhibit the aerobic glycolysis of leiomyosarcoma cells, performed in a model in which tissue-isolated xenografts were perfused in situ with blood collected from healthy adult humans following melatonin supplementation [39]. Compared to previous studies, our study was performed with a normal cell line, rather than a tumor cell line. Our finding may increase the knowledge of melatonin in cancer prevention.

In the present study, we revealed that melatonin suppressed nickel-induced aerobic glycolysis through blocking the HIF-1α/miR210/ISCU1/2 axis. This axis has been demonstrated to mediate aerobic glycolysis in multiple physiologic and pathologic processes associated with hypoxia [10–13]. Particularly, in cancer studies, abundant evidence has demonstrated that miR210 is overexpressed in multiple cancers [40]. In the present study, melatonin significantly decreased the level of miR210 through inactivating HIF-1α.
It is worth further investigating whether miR210 plays a role in melatonin anticancer capacity. Moreover, miR210 repressed the protein level of ISCU1/2, while melatonin maintained the ISCU1/2 level in our study. Considering the importance of FeS-dependent enzymes in energy metabolism, maintaining the ISCU1/2 level may contribute to a well-known protective effect of melatonin that attenuates mitochondria dysfunction [26].

The key step of melatonin suppressing aerobic glycolysis in our present study was to destabilize HIF-1α. As reviewed by Vriend and Reiter, melatonin destabilizes HIF-1α through different mechanisms, either suppressing synthesis or promoting degradation, according to cell type and treatment condition [9]. Although PHD is considered an oxygen sensor in the cell responses to hypoxia, other factors are also critical for its activity, such as ROS, Fe2+, and 2-oxoglutarate. We used several compounds to test the possible mechanism of melatonin destabilization of nickel-induced HIF-1α. α-KG, the substrate for PHD in HIF-1α hydroxylation, blocked nickel-induced HIF-1α, while 2-DG, the inhibitor of glucose utilization, had a similar effect. Although α-KG and 2-DG destabilized HIF-1α in accordance with a previous study [14], both failed to inhibit the upregulation of miR210. A plethora of literature has documented that miR210 is controlled by HIF-1α [41]. However, negative feedback by miR210 in inhibiting HIF-1α expression was also reported [42]. Whether α-KG or 2-DG complicates the cross effects between miR210 and HIF-1α warrants further investigation. The mTOR signaling pathway also participates in the transcription and degradation of HIF-1α because rapamycin attenuates both the increase in HIF-1α protein and transcription activity under low oxygen or CoCl2 exposure conditions [43]. In our study, with the same treatment procedure of melatonin, rapamycin did not work out on HIF-1α accumulation and miR210 upregulation. We also found that the phosphorylation level of mTOR was suppressed by Ni
treatment (data was not shown). These results indicated that the mTOR signaling pathway may play less important roles in nickel-induced HIF-1α accumulation.

It has been known for some time that ROS inactivates PHD; however, the significance of ROS in HIF-1α signal activation remains controversy [4]. Because ROS are usually also increased in hypoxia, it is hard to clarify which is the primary inducer, lower oxygen or ROS, for PHD inhibition. Regarding the chemical-mimic hypoxia effect induced by cobalt or nickel, a widely accepted hypothesis for PHD inhibition is that they belong to transition metal elements and disturb the homeostasis of the iron ion [44]. However, the disturbance of nickel on iron is not specific to PHD. Because of the unique role of iron in biochemical reactions, any perturbation in iron utilization inevitably induces ROS generation, especially the inactivation of metabolic enzymes in mitochondria [45]. Therefore, the nickel-induced ROS cannot be excluded for HIF-1α accumulation.

In our present study, both melatonin and NAC abolished the nickel-induced activation of the HIF-1α/miR210/ISCU axis. Based on their well-known ROS-scavenging capability, our data supported that ROS are the main inducers of PHD inhibition in nickel exposure. Additionally, melatonin more efficiently destabilized the nickel-induced HIF-1α than it did on MG132-caused HIF-1α accumulation. This result indicated that melatonin exerted its effect on PHD, rather than the following proteasomal degradation. However, this result is not in accordance with the study reported by Park et al., in which melatonin significantly reduced MG132-caused HIF-1α accumulation [25]. This contradiction may be attributed to the different cell background and MG132 treatment procedure.

In summary, our study demonstrated that melatonin repressed nickel-induced aerobic glycolysis in normal cells through blocking activation of the HIF-1α/miR210/ISCU1/2 axis. This effect depended on its capability of ROS scavenging, by which melatonin maintained the PHD activity in HIF-1α degradation (Figure 9). The investigation on ROS-mediated HIF-1α/miR210/ISCU axis activation and its roles in aerobic glycolysis may open a new sight into the knowledge of oxidative stress-induced diseases.

**Abbreviations**

- HIF-1α: Hypoxia-inducible factor 1α
- ROS: Reactive oxygen species
- miR210: MicroRNA210
- ISCU1/2: Iron-sulfur cluster assembly scaffold protein
- NAC: N-Acetylcysteine
- FeS: Iron-sulfur cluster
- OXPHOS: Oxidative phosphorylation
- PHD: Prolyl-hydroxylase enzymes
- CCK8: Cell counting kit-8
- LDH: Lactate dehydrogenase
- PFK: Phosphofructokinase
- ATP: Adenosine-5′-triphosphate
- EMSA: Electrophoresis mobility shift assay
- BrPA: Bromopyruvic acid
- mTOR: Mechanistic target of rapamycin

**Data Availability**

The data used to support the findings of this study are available from the corresponding author upon request.

**Conflicts of Interest**

The authors declare that no conflict of interest exists.

**Authors’ Contributions**

Zhou Zhou and Mindi He conceived and designed the study. Chao Zhou, Yonghui Lu, Ling Mao, Yu Xi, Xiang Mei, and Xue Wang performed the experiments. Mindi He and Chao Zhou conducted the data acquisition and analysis. Zhou Zhou and Mindi He wrote the manuscript. Lei Zhang and Zhengping Yu reviewed and edited manuscript preparation.

**Acknowledgments**

We thank Dr. Chunhai Chen, Dr. Huifeng Pi, Dr. Fenghua Qian, and Dr. Weixia Duan for their hospitality and professional technical assistance. This work was supported by a grant from the National Natural Science Foundation of China (No. 81872596), a supporting grant from the Key Laboratory of Electromagnetic Radiation Protection, Ministry of Education, China, and an Innovation Project Grant from the Army Medical University, China (2019XYY01).

**References**

[1] International Agency for Research on Cancer, “Chromium, Nickel and Welding,” IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol 49, pp. 1–648, 1990.

[2] H. Chen and M. Costa, “Effect of soluble nickel on cellular energy metabolism in A549 cells,” Experimental Biology and Medicine (Maywood, N.J.), vol. 231, no. 9, pp. 1474–1480, 2016.
[3] M. He, Y. Lu, S. Xu et al., “Mirna-210 modulates a nickel-induced cellular energy metabolism shift by repressing the iron-sulfur cluster assembly proteins Iscu1/2 in Neuro-2a cells,” Cell Death & Disease, vol. 5, no. 2, p. e1090, 2014.

[4] P. Maxwell and K. Salnikow, “Hif-1, an oxygen and metal responsive transcription factor,” Cancer Biology & Therapy, vol. 3, no. 1, pp. 29–35, 2014.

[5] O. Warburg, F. Wind, and E. Negelein, “The metabolism of tumors in the body,” Journal of General Physiology, vol. 8, no. 6, pp. 519–530, 1927.

[6] D. E. Blask, R. T. Dauchy, E. M. Dauchy et al., “Light exposure at night disrupts host/cancer circadian regulatory dynamics: impact on the Warburg effect, lipid signaling and tumor growth prevention,” PLoS One, vol. 9, no. 8, p. e102776, 2014.

[7] S. Devic, “Warburg effect—a consequence or the cause of carcinogenesis?,” Journal of Cancer, vol. 7, no. 7, pp. 817–822, 2016.

[8] S. Y. Chan, Y. Y. Zhang, C. Hemann, C. E. Mahoney, J. L. Zweier, and J. Loscalzo, “Microrna-210 controls mitochondrial metabolism during hypoxia by repressing the iron-sulfur cluster assembly proteins ISC1U12,” Cell Metabolism, vol. 10, no. 4, pp. 273–284, 2009.

[9] J. Vriend and R. J. Reiter, “Melatonin and the Von Hippel-Lindau/Hif-1 oxygen sensing mechanism: a review,” Biochimica et Biophysica Acta, vol. 1865, no. 2, pp. 176–183, 2016.

[10] D. C. Lee, R. Romero, J. S. Kim et al., “Mir-210 targets iron-sulfur cluster scaffold homologue in human trophoblast cell lines: siderosis of interstitial trophoblasts as a novel pathology of preterm preeclampsia and small-for-gestational-age pregnancies,” The American Journal of Pathology, vol. 179, no. 2, pp. 590–602, 2011.

[11] S. Hu, M. Huang, Z. Li et al., “MicroRNA-210 as a novel therapy for treatment of ischemic heart disease,” Circulation, vol. 122, no. 11, Supplement 1, pp. S124–S131, 2010.

[12] Z. Chen, Y. Li, H. Zhang, P. Huang, and R. Luthra, “Hypoxia-regulated microRNA-210 modulates mitochondrial function and decreases ISCU and COX10 expression,” Oncogene, vol. 29, no. 30, pp. 4362–4368, 2010.

[13] S. Muralimanoharan, A. Maloyan, J. Mele, C. Guo, L. G. Myatt, and L. Myatt, “Mir-210 modulates mitochondrial respiration in placenta with preeclampsia,” Placenta, vol. 33, no. 10, pp. 816–823, 2012.

[14] G. M. Tannahill, A. M. Curtis, J. Adamik et al., “Succinate is an inflammatory signal that induces IL-1β through HIF-1α,” Nature, vol. 496, no. 7444, pp. 238–242, 2013.

[15] K. Salnikow, W. G. An, G. Mellilo, M. V. Blagoslknnny, and M. Costa, “Nickel-induced transformation shifts the balance between Hif-1 and P53 transcription factors,” Carcinogenesis, vol. 20, no. 9, pp. 1819–1823, 1999.

[16] N. Goncalves, R. Rodrigues, B. Jardim-Persassi et al., “Molecular markers of angiogenesis and metastasis in lines of oral carcinoma after treatment with melanotin,” Anti-Cancer Agents in Medicinal Chemistry, vol. 14, no. 9, pp. 1302–1311, 2014.

[17] L. Yang, J. Zheng, R. Xu et al., “Melatonin suppresses hypoxia-induced migration of HUVECs via inhibition of ERK/Rac1 activation,” International Journal of Molecular Sciences, vol. 15, no. 8, pp. 14102–14121, 2014.

[18] S.-Y. Cho, H.-J. Lee, S.-J. Jeong et al., “Sphingosine kinase 1 pathway is involved in melanotin-induced HIF-1α inactivation in hypoxic PC-3 prostate cancer cells,” Journal of Pineal Research, vol. 51, no. 1, pp. 87–93, 2011.

[19] R. X. Wang, H. Liu, L. Xu, H. Zhang, and R. X. Zhou, “Involvement of nuclear receptor RZR/RORy in melanotin-induced HIF-1α inactivation in Sgc-7901 human gastric cancer cells,” Oncology Reports, vol. 34, no. 5, pp. 2541–2546, 2015.

[20] B. V. Jardim-Persassi, M. R. Lourenço, G. M. Doho et al., “Melatonin regulates angiogenic factors under hypoxia in breast cancer cell lines,” Anti-Cancer Agents in Medicinal Chemistry, vol. 16, no. 3, pp. 347–358, 2016.

[21] M. Dai, P. Cui, M. Yu, J. Han, H. Li, and R. Xiu, “Melatonin modulates the expression of VEGF and HIF-1 alpha induced by CcCl2 in cultured cancer cells,” Journal of Pineal Research, vol. 44, no. 2, pp. 121–126, 2008.

[22] J. Colombo, J. M. W. Maciel, L. C. Ferreira, R. F. Da Silva, and D. A. P. Zuccari, “Effects of melatonin on HIF-1α and VEGF expression and on the invasive properties of hepatocarcinoma cells,” Oncology Letters, vol. 12, no. 1, pp. 231–237, 2016.

[23] A. M. Sanchez-Sanchez, I. Antolin, N. Puente-Moncada et al., “Melatonin cytotoxicity is associated to Warburg effect inhibition in Ewing sarcoma cells,” PLoS One, vol. 10, no. 8, article e0135420, 2015.

[24] E. J. Sohn, G. Won, J. Lee, S. Lee, and S. H. Kim, “Upregulation of miRNA3195 and miRNA374b mediates the anti-angiogenic properties of melatonin in hypoxic PC-3 prostate cancer cells,” Journal of Cancer, vol. 6, no. 1, pp. 19–28, 2015.

[25] J. W. Park, M. S. Hwang, S. I. Suh, and W. K. Baek, “Melatonin down-regulates HIF-1 alpha expression through inhibition of protein translation in prostate cancer cells,” Journal of Pineal Research, vol. 46, no. 4, pp. 415–421, 2009.

[26] S. C. Xu, M. D. He, M. Zhong et al., “Melatonin protects against nickel-induced neurotoxicity in vitro by reducing oxidative stress and maintaining mitochondrial function,” Journal of Pineal Research, vol. 49, no. 1, pp. 86–94, 2010.

[27] A. Romero, E. Ramos, C. de Los Rios, J. Egea, J. del Pino, and R. J. Reiter, “A review of metal-catalyzed molecular damage: protection by melatonin,” Journal of Pineal Research, vol. 56, no. 4, pp. 343–370, 2014.

[28] T. Tsilaa and M. A. Teitell, “Techniques to monitor glycolysis,” Methods in Enzymology, vol. 542, pp. 91–114, 2014.

[29] G. G. Fletcher, F. E. Rossetto, J. D. Turnbull, and E. Nieboer, “Toxicity, uptake, and mutagenicity of particulate and soluble nickel compounds,” Environmental Health Perspectives, vol. 102, Supplement 3, pp. 69–79, 1994.

[30] H. Chen, T. Kluz, R. Zhang, and M. Costa, “Hypoxia and nickel inhibit histone demethylase JMJD1a and repress Sry2 expression in human bronchial epithelial BEAS-2B cells,” Carcinogenesis, vol. 31, no. 12, pp. 2136–2144, 2010.

[31] C. C. Jose, B. Xu, L. Jagnanath et al., “Epigenetic dysregulation by nickel through repressive chromatin domain disruption,” Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 40, pp. 14631–14636, 2014.

[32] Y. Ge, M. Bruno, N. Haykal-Coates et al., “Proteomic assessment of biochemical pathways that are critical to nickel-induced toxicity responses in human epithelial cells,” PLoS One, vol. 11, no. 9, article e0162522, 2016.

[33] T. Mikawa, M. E. LLeonart, A. Takaori-Kondo, N. Inagaki, M. Yokode, and H. Kondoh, “Dysregulated glycolysis as an oncogenic event,” Cellular and Molecular Life Sciences, vol. 72, no. 10, pp. 1881–1892, 2015.
S.-C. Cheng, J. Quintin, R. A. Cramer et al., “mTOR- and HIF-1-mediated aerobic glycolysis as metabolic basis for trained immunity,” *Science*, vol. 345, no. 6204, p. 1250684, 2014.

N. Xie, Z. Tan, S. Banerjee et al., “Glycolytic reprogramming in myofibroblast differentiation and lung fibrosis,” *American Journal of Respiratory and Critical Care Medicine*, vol. 192, no. 12, pp. 1462–1474, 2015.

A. Korkmaz, R. J. Reiter, T. Topal, L. C. Manchester, S. Oter, and D. X. Tan, “Melatonin: an established antioxidant worthy of use in clinical trials,” *Molecular Medicine*, vol. 15, no. 1-2, pp. 43–50, 2009.

R. Reiter, S. Rosales-Corral, D.-X. Tan et al., “Melatonin, a full service anti-cancer agent: inhibition of initiation, progression and metastasis,” *International Journal of Molecular Sciences*, vol. 18, no. 4, p. 843, 2017.

D. Hevia, P. Gonzalez-Menendez, M. Fernandez-Fernandez et al., “Melatonin Decreases Glucose Metabolism in Prostate Cancer Cells: A 13C Stable Isotope-Resolved Metabolomic Study,” *International Journal of Molecular Sciences*, vol. 18, no. 8, p. 1620, 2017.

L. Mao, R. T. Dauchy, D. E. Blask et al., “Melatonin suppression of aerobic glycolysis (Warburg effect), survival signalling and metastasis in human leiomyosarcoma,” *Journal of Pineal Research*, vol. 60, no. 2, pp. 167–177, 2016.

A. Bavelloni, G. Ramazzotti, A. Poli et al., “Mirna-210: a current overview,” *Anticancer Research*, vol. 37, no. 12, pp. 6511–6521, 2017.

Q. Qin, W. Furong, and L. Baosheng, “Multiple functions of hypoxia-regulated Mir-210 in cancer,” *Journal of Experimental & Clinical Cancer Research*, vol. 33, no. 1, p. 50, 2014.

H. Wang, H. Flach, M. Onizawa, L. Wei, M. T. McManus, and A. Weiss, “Negative regulation of Hif1a expression and TH17 differentiation by the hypoxia-regulated microRNA mir-210,” *Nature Immunology*, vol. 15, no. 4, pp. 393–401, 2014.

C. C. Hudson, M. Liu, G. G. Chiang et al., “Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin,” *Molecular and Cellular Biology*, vol. 22, no. 20, pp. 7004–7014, 2002.

G. S. Kang, Q. Li, H. Chen, and M. Costa, “Effect of metal ions on Hif-1alpha and Fe homeostasis in human A549 cells,” *Mutation Research*, vol. 610, no. 1-2, pp. 48–55, 2006.

N. P. Mena, P. J. Urrutia, F. Lourido, C. M. Carrasco, and M. T. Nunez, “Mitochondrial iron homeostasis and its dysfunctions in neurodegenerative disorders,” *Mitochondrion*, vol. 21, pp. 92–105, 2015.